Global Nifedipine Controlled-release Tablets 麻豆原创 Growth 2024-2030

Publication ID:

LPI08248175

Publication Date:

August 13, 2024

Pages:

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

Nifedipine controlled-release tablets are a type of medication used primarily to treat high blood pressure(hypertension)and certain types of chest pain(angina).Nifedipine belongs to a class of drugs known as calcium channel blockers.These tablets are formulated to release the medication slowly over time,which helps maintain a steady level of the drug in the body and can prolong its therapeutic effect.
The global Nifedipine Controlled-release Tablets market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.
The 鈥淣ifedipine Controlled-release Tablets Industry Forecast鈥� looks at past sales and reviews total world Nifedipine Controlled-release Tablets sales in 2023, providing a comprehensive analysis by region and market sector of projected Nifedipine Controlled-release Tablets sales for 2024 through 2030. With Nifedipine Controlled-release Tablets sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Nifedipine Controlled-release Tablets industry.
This Insight Report provides a comprehensive analysis of the global Nifedipine Controlled-release Tablets landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Nifedipine Controlled-release Tablets portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Nifedipine Controlled-release Tablets market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Nifedipine Controlled-release Tablets and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Nifedipine Controlled-release Tablets.
United States market for Nifedipine Controlled-release Tablets is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for Nifedipine Controlled-release Tablets is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for Nifedipine Controlled-release Tablets is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key Nifedipine Controlled-release Tablets players cover Bayer, Shanghai Shyndec Pharma, Simcere, Qingdao Baiyang Pharmaceutical, China Resources Double Crane Limin Pharmaceutical (Jinan), etc. In terms of revenue, the global two largest companies occupied for a share nearly
% in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of Nifedipine Controlled-release Tablets market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Generic Drug
Original Drug
Segmentation by Application:
Hospital and Clinic
Retail Pharmacies
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Bayer
Shanghai Shyndec Pharma
Simcere
Qingdao Baiyang Pharmaceutical
China Resources Double Crane Limin Pharmaceutical (Jinan)
Hefei Cube Pharma
Deyao Pharma
Apichope
Nanjing EASEHEAL Pharma
Beijing Honglin Pharma
Key Questions Addressed in this Report
What is the 10-year outlook for the global Nifedipine Controlled-release Tablets market?
What factors are driving Nifedipine Controlled-release Tablets market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Nifedipine Controlled-release Tablets market opportunities vary by end market size?
How does Nifedipine Controlled-release Tablets break out by Type, by Application?

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Nifedipine Controlled-release Tablets Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Nifedipine Controlled-release Tablets by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Nifedipine Controlled-release Tablets by Country/Region, 2019, 2023 & 2030
2.2 Nifedipine Controlled-release Tablets Segment by Type
2.2.1 Generic Drug
2.2.2 Original Drug
2.3 Nifedipine Controlled-release Tablets Sales by Type
2.3.1 Global Nifedipine Controlled-release Tablets Sales 麻豆原创 Share by Type (2019-2024)
2.3.2 Global Nifedipine Controlled-release Tablets Revenue and 麻豆原创 Share by Type (2019-2024)
2.3.3 Global Nifedipine Controlled-release Tablets Sale Price by Type (2019-2024)
2.4 Nifedipine Controlled-release Tablets Segment by Application
2.4.1 Hospital and Clinic
2.4.2 Retail Pharmacies
2.4.3 Other
2.5 Nifedipine Controlled-release Tablets Sales by Application
2.5.1 Global Nifedipine Controlled-release Tablets Sale 麻豆原创 Share by Application (2019-2024)
2.5.2 Global Nifedipine Controlled-release Tablets Revenue and 麻豆原创 Share by Application (2019-2024)
2.5.3 Global Nifedipine Controlled-release Tablets Sale Price by Application (2019-2024)
3 Global by Company
3.1 Global Nifedipine Controlled-release Tablets Breakdown Data by Company
3.1.1 Global Nifedipine Controlled-release Tablets Annual Sales by Company (2019-2024)
3.1.2 Global Nifedipine Controlled-release Tablets Sales 麻豆原创 Share by Company (2019-2024)
3.2 Global Nifedipine Controlled-release Tablets Annual Revenue by Company (2019-2024)
3.2.1 Global Nifedipine Controlled-release Tablets Revenue by Company (2019-2024)
3.2.2 Global Nifedipine Controlled-release Tablets Revenue 麻豆原创 Share by Company (2019-2024)
3.3 Global Nifedipine Controlled-release Tablets Sale Price by Company
3.4 Key Manufacturers Nifedipine Controlled-release Tablets Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Nifedipine Controlled-release Tablets Product Location Distribution
3.4.2 Players Nifedipine Controlled-release Tablets Products Offered
3.5 麻豆原创 Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 麻豆原创 M&A Activity & Strategy
4 World Historic Review for Nifedipine Controlled-release Tablets by Geographic Region
4.1 World Historic Nifedipine Controlled-release Tablets 麻豆原创 Size by Geographic Region (2019-2024)
4.1.1 Global Nifedipine Controlled-release Tablets Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Nifedipine Controlled-release Tablets Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Nifedipine Controlled-release Tablets 麻豆原创 Size by Country/Region (2019-2024)
4.2.1 Global Nifedipine Controlled-release Tablets Annual Sales by Country/Region (2019-2024)
4.2.2 Global Nifedipine Controlled-release Tablets Annual Revenue by Country/Region (2019-2024)
4.3 Americas Nifedipine Controlled-release Tablets Sales Growth
4.4 APAC Nifedipine Controlled-release Tablets Sales Growth
4.5 Europe Nifedipine Controlled-release Tablets Sales Growth
4.6 Middle East & Africa Nifedipine Controlled-release Tablets Sales Growth
5 Americas
5.1 Americas Nifedipine Controlled-release Tablets Sales by Country
5.1.1 Americas Nifedipine Controlled-release Tablets Sales by Country (2019-2024)
5.1.2 Americas Nifedipine Controlled-release Tablets Revenue by Country (2019-2024)
5.2 Americas Nifedipine Controlled-release Tablets Sales by Type (2019-2024)
5.3 Americas Nifedipine Controlled-release Tablets Sales by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Nifedipine Controlled-release Tablets Sales by Region
6.1.1 APAC Nifedipine Controlled-release Tablets Sales by Region (2019-2024)
6.1.2 APAC Nifedipine Controlled-release Tablets Revenue by Region (2019-2024)
6.2 APAC Nifedipine Controlled-release Tablets Sales by Type (2019-2024)
6.3 APAC Nifedipine Controlled-release Tablets Sales by Application (2019-2024)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Nifedipine Controlled-release Tablets by Country
7.1.1 Europe Nifedipine Controlled-release Tablets Sales by Country (2019-2024)
7.1.2 Europe Nifedipine Controlled-release Tablets Revenue by Country (2019-2024)
7.2 Europe Nifedipine Controlled-release Tablets Sales by Type (2019-2024)
7.3 Europe Nifedipine Controlled-release Tablets Sales by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Nifedipine Controlled-release Tablets by Country
8.1.1 Middle East & Africa Nifedipine Controlled-release Tablets Sales by Country (2019-2024)
8.1.2 Middle East & Africa Nifedipine Controlled-release Tablets Revenue by Country (2019-2024)
8.2 Middle East & Africa Nifedipine Controlled-release Tablets Sales by Type (2019-2024)
8.3 Middle East & Africa Nifedipine Controlled-release Tablets Sales by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Nifedipine Controlled-release Tablets
10.3 Manufacturing Process Analysis of Nifedipine Controlled-release Tablets
10.4 Industry Chain Structure of Nifedipine Controlled-release Tablets
11 麻豆原创ing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Nifedipine Controlled-release Tablets Distributors
11.3 Nifedipine Controlled-release Tablets Customer
12 World Forecast Review for Nifedipine Controlled-release Tablets by Geographic Region
12.1 Global Nifedipine Controlled-release Tablets 麻豆原创 Size Forecast by Region
12.1.1 Global Nifedipine Controlled-release Tablets Forecast by Region (2025-2030)
12.1.2 Global Nifedipine Controlled-release Tablets Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country (2025-2030)
12.3 APAC Forecast by Region (2025-2030)
12.4 Europe Forecast by Country (2025-2030)
12.5 Middle East & Africa Forecast by Country (2025-2030)
12.6 Global Nifedipine Controlled-release Tablets Forecast by Type (2025-2030)
12.7 Global Nifedipine Controlled-release Tablets Forecast by Application (2025-2030)
13 Key Players Analysis
13.1 Bayer
13.1.1 Bayer Company Information
13.1.2 Bayer Nifedipine Controlled-release Tablets Product Portfolios and Specifications
13.1.3 Bayer Nifedipine Controlled-release Tablets Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Bayer Main Business Overview
13.1.5 Bayer Latest Developments
13.2 Shanghai Shyndec Pharma
13.2.1 Shanghai Shyndec Pharma Company Information
13.2.2 Shanghai Shyndec Pharma Nifedipine Controlled-release Tablets Product Portfolios and Specifications
13.2.3 Shanghai Shyndec Pharma Nifedipine Controlled-release Tablets Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 Shanghai Shyndec Pharma Main Business Overview
13.2.5 Shanghai Shyndec Pharma Latest Developments
13.3 Simcere
13.3.1 Simcere Company Information
13.3.2 Simcere Nifedipine Controlled-release Tablets Product Portfolios and Specifications
13.3.3 Simcere Nifedipine Controlled-release Tablets Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 Simcere Main Business Overview
13.3.5 Simcere Latest Developments
13.4 Qingdao Baiyang Pharmaceutical
13.4.1 Qingdao Baiyang Pharmaceutical Company Information
13.4.2 Qingdao Baiyang Pharmaceutical Nifedipine Controlled-release Tablets Product Portfolios and Specifications
13.4.3 Qingdao Baiyang Pharmaceutical Nifedipine Controlled-release Tablets Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 Qingdao Baiyang Pharmaceutical Main Business Overview
13.4.5 Qingdao Baiyang Pharmaceutical Latest Developments
13.5 China Resources Double Crane Limin Pharmaceutical (Jinan)
13.5.1 China Resources Double Crane Limin Pharmaceutical (Jinan) Company Information
13.5.2 China Resources Double Crane Limin Pharmaceutical (Jinan) Nifedipine Controlled-release Tablets Product Portfolios and Specifications
13.5.3 China Resources Double Crane Limin Pharmaceutical (Jinan) Nifedipine Controlled-release Tablets Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 China Resources Double Crane Limin Pharmaceutical (Jinan) Main Business Overview
13.5.5 China Resources Double Crane Limin Pharmaceutical (Jinan) Latest Developments
13.6 Hefei Cube Pharma
13.6.1 Hefei Cube Pharma Company Information
13.6.2 Hefei Cube Pharma Nifedipine Controlled-release Tablets Product Portfolios and Specifications
13.6.3 Hefei Cube Pharma Nifedipine Controlled-release Tablets Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 Hefei Cube Pharma Main Business Overview
13.6.5 Hefei Cube Pharma Latest Developments
13.7 Deyao Pharma
13.7.1 Deyao Pharma Company Information
13.7.2 Deyao Pharma Nifedipine Controlled-release Tablets Product Portfolios and Specifications
13.7.3 Deyao Pharma Nifedipine Controlled-release Tablets Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 Deyao Pharma Main Business Overview
13.7.5 Deyao Pharma Latest Developments
13.8 Apichope
13.8.1 Apichope Company Information
13.8.2 Apichope Nifedipine Controlled-release Tablets Product Portfolios and Specifications
13.8.3 Apichope Nifedipine Controlled-release Tablets Sales, Revenue, Price and Gross Margin (2019-2024)
13.8.4 Apichope Main Business Overview
13.8.5 Apichope Latest Developments
13.9 Nanjing EASEHEAL Pharma
13.9.1 Nanjing EASEHEAL Pharma Company Information
13.9.2 Nanjing EASEHEAL Pharma Nifedipine Controlled-release Tablets Product Portfolios and Specifications
13.9.3 Nanjing EASEHEAL Pharma Nifedipine Controlled-release Tablets Sales, Revenue, Price and Gross Margin (2019-2024)
13.9.4 Nanjing EASEHEAL Pharma Main Business Overview
13.9.5 Nanjing EASEHEAL Pharma Latest Developments
13.10 Beijing Honglin Pharma
13.10.1 Beijing Honglin Pharma Company Information
13.10.2 Beijing Honglin Pharma Nifedipine Controlled-release Tablets Product Portfolios and Specifications
13.10.3 Beijing Honglin Pharma Nifedipine Controlled-release Tablets Sales, Revenue, Price and Gross Margin (2019-2024)
13.10.4 Beijing Honglin Pharma Main Business Overview
13.10.5 Beijing Honglin Pharma Latest Developments
14 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.